RxDoctor Payments Data

Kimberly Miles

Psychiatric/Mental Health · Troy, ALNPI 1811602469

Payments from drug & device makers

$1,371in general payments, 2019–2025

Across 59 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$333
  • Neurocrine Biosciences, Inc.$295
  • Alkermes, Inc.$235
  • Vanda Pharmaceuticals Inc.$220
  • Johnson & Johnson$62
  • AbbVie$61
  • plus $165 from 5 others

What the payments were for

  • Food & beverage$1,371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,371 in reported general payments places this provider in the 55th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$1,226
Medicare patients
13
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate76$202,039
Abilify MaintenaAripiprazole60$175,832
IngrezzaValbenazine Tosylate11$87,148
AristadaAripiprazole Lauroxil21$54,620
AuvelityDextromethorphan Hbr/Bupropion13$12,249
Haloperidol Decanoate94$4,480
Fluphenazine Decanoate26$1,961
Olanzapine96$1,447
Aripiprazole35$1,145
Quetiapine Fumarate48$876
Trazodone Hcl66$682
Haloperidol31$576
Benztropine Mesylate40$518
Risperidone21$382
Hydroxyzine Pamoate19$339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$62$202,03976 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$38$175,83260 claims
Neurocrine Biosciences, Inc.Ingrezza$295$87,14811 claims
Alkermes, Inc.Aristada$235$54,62021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Troy

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →